Equities Analysts Set Expectations for AVBP FY2025 Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at Lifesci Capital decreased their FY2025 earnings per share estimates for ArriVent BioPharma in a research report issued on Monday, March 3rd. Lifesci Capital analyst S. Slutsky now anticipates that the company will earn ($3.97) per share for the year, down from their prior estimate of ($3.80). The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma’s FY2026 earnings at ($4.49) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.18.

Separately, HC Wainwright increased their price objective on shares of ArriVent BioPharma from $36.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday, January 22nd.

ArriVent BioPharma Stock Performance

AVBP stock opened at $22.47 on Thursday. The company’s 50 day moving average price is $26.40 and its 200 day moving average price is $27.16. ArriVent BioPharma has a fifty-two week low of $14.35 and a fifty-two week high of $36.37.

Hedge Funds Weigh In On ArriVent BioPharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of ArriVent BioPharma during the 4th quarter worth approximately $31,000. Tower Research Capital LLC TRC lifted its position in ArriVent BioPharma by 773.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,599 shares of the company’s stock valued at $43,000 after acquiring an additional 1,416 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in ArriVent BioPharma in the fourth quarter valued at $73,000. KLP Kapitalforvaltning AS purchased a new position in shares of ArriVent BioPharma during the fourth quarter worth about $83,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of ArriVent BioPharma during the fourth quarter worth about $190,000. 9.48% of the stock is owned by institutional investors and hedge funds.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.